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Abstract
Mont Blanc, the summit of Western Europe, is a popular but demanding high-altitude
ascent. Drug use is thought to be widespread among climbers attempting this summit, not
only to prevent altitude illnesses, but also to boost physical and/or psychological capacities.
This practice may be unsafe in this remote alpine environment. However, robust data on
medication during the ascent of Mont Blanc are lacking. Individual urine samples from male
climbers using urinals in mountain refuges on access routes to Mont Blanc (Goûter and
Cosmiques mountain huts) were blindly and anonymously collected using a hidden auto-
matic sampler. Urine samples were screened for a wide range of drugs, including diuretics,
glucocorticoids, stimulants, hypnotics and phosphodiesterase 5 (PDE-5) inhibitors. Out of
430 samples analyzed from both huts, 35.8% contained at least one drug. Diuretics (22.7%)
and hypnotics (12.9%) were the most frequently detected drugs, while glucocorticoids
(3.5%) and stimulants (3.1%) were less commonly detected. None of the samples con-
tained PDE-5 inhibitors. Two substances were predominant: the diuretic acetazolamide
(20.6%) and the hypnotic zolpidem (8.4%). Thirty three samples were found positive for at
least two substances, the most frequent combination being acetazolamide and a hypnotic
(2.1%). Based on a novel sampling technique, we demonstrate that about one third of the
urine samples collected from a random sample of male climbers contained one or several
drugs, suggesting frequent drug use amongst climbers ascending Mont Blanc. Our data
suggest that medication primarily aims at mitigating the symptoms of altitude illnesses,
rather than enhancing performance. In this hazardous environment, the relatively high prev-
alence of hypnotics must be highlighted, since these molecules may alter vigilance.
PLOS ONE | DOI:10.1371/journal.pone.0156786 June 2, 2016 1 / 12
a11111
OPEN ACCESS
Citation: Robach P, Trebes G, Lasne F, Buisson C,
Méchin N, Mazzarino M, et al. (2016) Drug Use on
Mont Blanc: A Study Using Automated Urine
Collection. PLoS ONE 11(6): e0156786. doi:10.1371/
journal.pone.0156786
Editor: Kathrin Eller, Medical University of Graz,
AUSTRIA
Received: February 15, 2016
Accepted: May 19, 2016
Published: June 2, 2016
Copyright: © 2016 Robach et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
S1 Table contains individual data of drug
concentrations in urine samples.
Funding: This study was supported by the Agence
Française de Lutte contre le Dopage, the Fondation
Petzl and the Fédération Française des Clubs Alpins
et de Montagne. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Mont Blanc (4810m altitude), at the border between France and Italy, is the highest mountain
in Western Europe and one of the most climbed summits in the world. About 35,000 people
attempt to reach the summit every year [1]. Despite its popularity, an ascent of Mont Blanc is
considered to be a highly demanding exercise requiring good aerobic performance, technical
expertise and altitude acclimatization. However anecdotal evidence indicate that many people
attempting the summit do not have the experience, physical condition or skill-set required,
and/or are not sufficiently well-acclimatized [2]. This may explain why exhaustion is com-
monly reported among Mont Blanc climbers.
To avoid altitude related illnesses and/or exhaustion, and ultimately to increase their chance
of reaching the summit, climbers may use medications, with or without prescription. Several
categories of drugs may be relevant to this purpose: first, since the rapid altitude gain increases
the risk of acute mountain sickness, prophylactic treatments with acetazolamide [3] or gluco-
corticoids [4] may be considered; second, the potential risk of exhaustion may also incite some
climbers to take stimulants [5]; third, the performance-enhancing effect of phosphodiesterase 5
(PDE-5) inhibitors at high altitude may prompt people to use these drugs to optimize their
ascent [6]; and fourth, high-altitude sleep disturbances that may otherwise compromise the
summit push can be alleviated by specific hypnotic drugs [7, 8].
It may be worthwhile to highlight that, with the exception of hypnotics, all the drugs men-
tioned above possess a favorable effect at altitude [6, 9, 10]; acetazolamide, glucocorticoids and
stimulants are indeed banned in sports, being included in the list of prohibited substances of
the World Anti-Doping Agency (WADA) [11]. As alpinism is not subject to anti-doping rules,
any objections to the use of medications are based on ethical or safety concerns. Indeed,
although prophylactic medication against altitude sickness is justified in some cases [12], drug
use is always associated with some risks. First, all the above mentioned drugs have side effects
whose consequences can become highly problematic in a remote alpine environment: acetazol-
amide increases urine frequency that may exaggerate dehydration; short-term treatment with
glucocorticoids may induce hyperglycemia [13]; stimulants may lead to cardiovascular compli-
cations, hypertension, and/or thermoregulatory problems [14]; PDE-5 inhibitors are com-
monly associated with headache and rarely with visual disturbances; finally, residual effects of
hypnotics may alter psychomotor and cognitive functioning [15]. Second, if drugs are used to
push physical or psychological barriers and to delay the onset of fatigue in order to reach the
summit, they may, ultimately, lead to greater levels of exhaustion and/or decompensation dur-
ing the climb or the descent. Third, in the case they are taken to induce sleep the night before
the ascent, they can cause reduced reactivity in potential emergencies.
Except for acetazolamide, which is widely used during high altitude fast climbs [16], there is
limited information available on the prevalence of ergogenic drug use amongst mountaineers. One
case report [17] and numerous anecdotic reports of drug use [18] suggest that the practice is wide-
spread, notably on iconic summits. Reinhold Messner, the renowned Italian mountaineer, has sug-
gested that up to 90% of those attempting to conquer Mount Everest may use drugs [19]. To the
best of our knowledge, drug consumption amongst alpinists attempting to ascendMont Blanc has
never been evaluated based on the direct analysis of their residues/metabolites in body fluids.
The aim of this study was to verify whether the use of performance-enhancing drugs is prev-
alent amongst alpinists ascending Mont Blanc. To quantify this phenomenon, we developed
and conducted an automated, blinded collection of individual urine samples, in the mountain
huts located on the two main access routes to the summit. The urine samples were analyzed for
a large number of drugs/metabolites, belonging in particular to the classes of diuretics, gluco-
corticoids, stimulants, hypnotics and PDE-5 inhibitors.
Performance-Enhancing Drug Use on Mont Blanc
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Methods
Ethical aspects
As this study was designed to investigate a phenomenon which is generally negatively per-
ceived (performance-enhancing drug use), it is susceptible to a high level of selection bias i.e.
people using drugs may want to hide this fact and not be included in the study. In order to
reduce this bias, participants were not individually informed about the study and consent was
not sought. A notice in French and in English was posted on the main entrance to the bath-
room area (serving all toilets and urinals), saying that urine samples might be randomly col-
lected for analysis, without specifying the purpose of the analyses. For ethical reasons, no
clinical or demographic information was collected. Furthermore, we took all possible precau-
tions to make the identification of subjects impossible. Study Ethics approval was obtained on
January 14th 2013 (CECIC Rhône-Alpes-Auvergne, Clermont-Ferrand, France, IRB: 5891).
Formal authorizations to modify one urinal in each of the high-altitude huts were obtained
from the Fédération Française des Clubs Alpins et de Montagne (Goûter hut) and Compagnie
des Guides de Chamonix (Cosmiques huts).
Ascent patterns of Mont Blanc
Two popular routes lead to the top of Mont Blanc. The first one, via Goûter hut and “Arête des
Bosses”, starts from the “Nid d’Aigle” train station (2272m). Climbers typically leave the valley
in the morning and reach the Goûter hut (3845m) in the afternoon. They summit Mont Blanc
the next morning and return in the valley in the afternoon. Total time spent above 2500m is
around 30 hours. The second one, via Cosmiques hut and “Trois Mont Blanc”, starts from
“Aiguille du Midi” cable car station (3842m). Climbers typically leave the valley in the after-
noon and reach the Cosmiques hut (3615m) following a one-hour climb. They attain Mont
Blanc the next morning and return in the valley in the afternoon. Total time spent above
2500m is around 24 hours.
Automatic collection of urine samples
Urine samples were collected from the urinals used by male individuals at the Goûter and the
Cosmiques mountain huts. Since our system could not be adapted to toilets where urine is
mixed with water systematically, women could not be included in the present analysis. Each
individual sample was collected in a separate container in a custom-made invisible and inaudi-
ble automatic system (Fig 1). The multi-sample system (24 × 500 ml) operated via an auto-
matic, battery-driven water sampler (portable model 3700C, Teledyne ISCO, Lincoln NE,
USA) connected to a liquid presence detector (model LD90) with a detection threshold of
25 ± 10 micro siemens (μS)/cm. The intake suction tubing (one meter) and the detector (modi-
fied to reduce its size) were positioned above the syphon on the drainpipe of one of the urinals
in each hut (Fig 1). The average volume of urine collected in each sample was 67 ml. The sam-
pler was acoustically isolated and installed in an adjacent service duct. When the urinal was
flushed, a water sample was drawn. In both huts, domestic water obtained by melting ice from
the glacier was characterized by very low conductivity (< 25 μS/cm). Thus, to ensure proper
water detection by the system, water conductivity was increased with salt tablets (Axal, Esco,
Hannover, Germany) positioned in the water inlet circuit. This procedure did not interfere
with subsequent drug analyzes. An air purge was initiated before and after each sample.
The sampling procedure took place over 14 days for the Cosmiques hut and 21 days for the
Goûter hut between July and September 2013. In each hut, one urinal was fitted with the sam-
pling system. At the Cosmiques hut, which serves Mont Blanc and other peaks, the sampler
Performance-Enhancing Drug Use on Mont Blanc
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Fig 1. Diagram of the automatic urine collection system.①mobile soundproof box with a pulley block;② battery;③ controller, motor and software;④
roller pump;⑤ sampler’s hood;⑥ rotating sampler arm;⑦multi-container cassette (24 × 500 ml);⑧ fixed soundproof support base;⑨ siphon passage;⑩
modified siphon;⑪ urinal;⑫ basket containing salt tablets;⑬manual flush;⑭ filter grid;⑮ funnel sieve (with holes);⑯ sampling tube;⑰ waterproof
electric wire;⑱ liquid presence detector, composed of two isolated wires entering the funnel through distinct holes. Bare wire ends (1 cm) are positioned
horizontally inside the funnel so as not to touch each other. It should be noted that with the present system, cross-contamination of urine may occur between
successive samples (see Methods). A possible improvement of the system, minimizing residual liquid volume and therefore potential contamination, would
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operated from 00:00 a.m. to 04:00 a.m. corresponding to the time of departures for Mont
Blanc. In all, the Cosmiques hut has three urinals and three toilets, all located in the same area
accessible 24h per day. At the Goûter hut, which only serves Mont Blanc, the sampler (located
at the restaurant level, for technical reasons) operated from 01:30 a.m. to 09:00 p.m. In all, the
Goûter hut has five urinals and six toilets, divided into three areas: 1) at the restaurant level
(two urinals and three toilets, area closed between 09:00 p.m. and 01:30 a.m.), 2) at the dormi-
tory first floor (two urinals and two toilets, area accessible 24h per day) and 3) at the dormitory
second floor (one urinal and one toilet, area accessible 24h per day). Sampling automatically
stopped after 24 samples (each sampling time was recorded), then a new clean multi-sample
cassette was inserted, the tube rinsed and the sampler reprogrammed for the next night. All
operations (programming, cleaning, maintenance, transport) were supervised by members of
the research team, with the assistance of a trained staff member in each hut. The full multi-
sample cassettes were stored at -20°C in the hut until being transported weekly by helicopter or
on foot to the laboratory in Chamonix. The experimental urinals were not used by the hut
staff.
Since our sampling process involved a residual volume of liquid in the tube (up to 4 ml),
contamination of the next sample could not be excluded. The rate of potential cross-sample
contamination was assessed during a separate on-site experiment, using urine samples titrated
with selected drugs. The rate of contamination between two successive urine samples (the first
titrated, the second blank) was 4.7% for betamethasone, 0.0% for prednisolone, 6.0% for tetra-
hydrocannabinol, 5.7% for acetazolamide and 12.8% for hydrochlorothiazide. These values
correspond to averages from two separate tests (urinary concentrations were measured in
duplicate for each test).
Analytical procedures
The urine samples were screened for diuretics, glucocorticoids and stimulants by the French
WADA-accredited laboratory (Département des Analyses, Agence Française de Lutte contre le
Dopage). Confirmatory analyses were performed for diuretics and some stimulants. A wider
screening by the same lab included other substances from the WADA 2016 list of prohibited
substances [11]: anabolic agents, beta-2 agonists, metabolic modulators, narcotics, cannabi-
noids and beta-blockers. PDE-5 inhibitors, benzodiazepines and related substances were ana-
lyzed (screening and confirmation) by the Italian WADA-accredited laboratory (Laboratorio
Antidoping, Federazione Medico Sportiva Italiana) following a specific analytical procedure
[20]. The list of the searched substances and the details of the analytical procedures are avail-
able in S1 File.
Data expression
Each substance was considered independently in the analysis. The status for each substance in
a urine sample could be negative, positive or contaminated. The latter was applied when the
concentration was less than or equal to that measured in the previous sample. We chose this
conservative approach to avoid any risk of including false positive results in our analysis. The
proportion of positive cases (in %) for a given substance was calculated as follows: number of
positive samples for this substance (number of samples analyzed in total–number of samples
contaminated by this substance) × 100.
consist in positioning the tip of the sampling tube (⑯) within the funnel (⑮) while maintaining the collector tube vertical throughout its course, by means of a
side hole in the upper part of the drainpipe. This change could not be implemented during the course of the study due to the complexity of the technical
modification in this extreme field environment.
doi:10.1371/journal.pone.0156786.g001
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We also calculated the rate of positive samples, whatever the type of substance. The status of
the whole sample could be positive if at least one substance was found positive in this sample,
regardless of other substances possibly contaminating the sample; negative if no substance
could be detected in this sample and no substance contaminated this sample; contaminated if
no substance was found positive in this sample and at least one substance considered as con-
tamination was found.
Data analysis
Data analysis was descriptive. Quantitative variables are expressed as proportions and a 95%
confidence interval (95% CI). Continuous variables are expressed as means and standard devia-
tions (SD). The precision of the estimation was calculated a priori. For a sample size of 400, a
two-sided 95% confidence interval for a single proportion using the large sample normal
approximation extends<0.05 from the observed proportion, for an expected proportion of 0.4
or lower (nQuery Advisor1 v7, Statistical Solutions Ltd, Cork, Ireland).
Results
Considering all 430 urine samples analyzed, the proportion of positive samples in both huts
was 35.8% (31.3–40.3%), that is 31.4% (24.1–38.7%) and 38.3% (32.5–44.1%) in the Cosmiques
and the Goûter huts, respectively. The proportion of negative samples was 48.8% (44.1–53.5%)
and contamination occurred in 15.3% (11.9–18.7%) of the samples. The classes of substances
most often detected in urine samples were diuretics and hypnotics (Table 1). Glucocorticoids
and stimulants were identified in urine samples to a lesser extent. No PDE-5 inhibitors were
detected in the urine samples. The wider screening found some other substances in the sam-
ples, such as cannabinoids, narcotics and beta-blockers. We detected neither anabolic agents,
nor beta-2 agonists.
In both huts, the main substances detected in urine samples were acetazolamide and zolpi-
dem (Table 1). Prednisone was the most frequently detected glucocorticoid, while caffeine and
the cocaine metabolite benzoylecgonine were the most often found stimulants. Oxazepam was
the most frequently detected anxiolytic hypnotic drug. Prevalence data were generally similar
between the two huts. Table 1 also reports the urine mean concentrations of the different
substances.
Drug combinations are presented in Table 2. In total, thirty-three urine samples were found
positive for at least two substances, the most frequent combinations being the association of
acetazolamide with a hypnotic (2.1%) followed by that of acetazolamide with a glucocorticoid
(1.9%). The combination of two diuretics (acetazolamide and hydrochlorothiazide) was seen in
0.9% of the samples.
Discussion
To our knowledge, this is the first study examining the prevalence of drug use based on
blinded, random urine sample collection. The selection of the target analytes was based on the
following criteria: i) enhancement of performance (based on the current anti-doping rules for
competitive sports); ii) therapeutical/preventive pharmacological treatments, and iii) safety
issues.
At least one drug was detected in about one in three urine samples collected from a random
sample of male individuals climbing the Mont Blanc. Two molecules were prevalent among
this set of urine samples: the diuretic acetazolamide and the hypnotic zolpidem. In contrast,
the prevalence of other substances potentially increasing physical performance at altitude, i.e.
glucocorticoids and stimulants, was low, and no PDE-5 inhibitors were detected. Finally, our
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Table 1. Prevalence and concentrations of drugs found in urine fromMont Blanc climbers.
Positive samples, % (95% CI) Concentrations, ng/ml
Substance Goûter hut Cosmiques hut Both huts Both huts
Mean ± SD (min-max)
Diuretics 24.9 (19.3–30.4) 19.1 (12.7–25.6) 22.7 (18.5–27.0)
Acetazolamide 22.4 (17.1–27.7) 17.6 (11.3–23.9) 20.6 (16.5–24.7) 44,630 ± 96,857 (20–491,100)*
Hydrochlorothiazide 1.9 (0.2–3.5) 1.3 (0.0–3.1) 1.6 (0.4–2.9) 1,935 ± 3,620 (4–10,048)*
Hypnotics 12.7 (8.4–17) 13.3 (7.6–19.1) 12.9 (9.5–16.4)
Zolpidem 8.2 (4.7–11.7) 8.7 (4.0–13.4) 8.4 (5.6–11.2) 9 ± 23 (0.1–127)*
Oxazepam 1.7 (0.0–3.4) 1.4 (0.0–3.3) 1.6 (0.3–2.8) 67 ± 85 (3–222)*
Zopiclone 1.3 (0.0–2.7) 1.4 (0.0–3.3) 1.3 (0.2–2.4) 185 ± 313 (11–739)*
Lorazepam 0.9 (0.0–2.2) 0.0 0.5 (0.0–1.3) 2,858 ± 3,816 (160–5,556)*
Bromazepam 0.4 0.0 0.3 23* (n = 1)
Zaleplon 0.0 0.7 0.3 3* (n = 1)
Brotizolam 0.0 0.7 0.3 1* (n = 1)
Glucocorticoids 3.7 (1.5–6.0) 3.3 (0.5–6.1) 3.5 (1.8–5.3)
Prednisone 2.2 (0.5–4.0) 1.3 (0.0–3.1) 1.9 (0.6–3.2) 391 ± 306 (11–776)
Prednisolone§ 1.9 (0.2–3.5) 1.3 (0.0–3.1) 1.6 (0.4–2.9) 939 ± 1,346 (11–3,823)
Betamethasone 1.1 (0.0–2.3) 0.0 0.7 (0.0–1.5) 25 ± 15 (13–42)
Budesonide 0.4 (0.0–1.1) 0.6 (0.0–1.9) 0.5 (0.0–1.1) 15 ± 6 (11–19)
Methylprednisolone 0.0 1.3 (0.0–3.1) 0.5 (0.0–1.1) 639 ± 831 (51–1,226)
Stimulants 4.1 (1.7–6.5) 1.3 (0.0–3.1) 3.1 (1.4–4.7)
Caffeine 1.1 (0.0–2.3) 0.6 (0.0–1.9) 0.9 (0.0–1.8) 7,725 ± 629 (7,000–8,300)
Benzoylecgonine‡ 1.1 (0.0–2.3) 0.0 0.7 (0.0–1.5) 253 ± 263 (68–439)*
Pseudoephedrine 0.7 (0.0–1.7) 0.0 0.5 (0.0–1.1) 10,940 ± 14,228 (879–21,000)
Ephedrine 0.4 0.0 0.2 9 (n = 1)
N-ethylnicotinamide 0.4 0.0 0.2 299 (n = 1)
Heptaminol 0.0 0.6 0.2 127* (n = 1)
Dihydrobupropion 0.4 0.0 0.2 665 (n = 1)
Cannabinoids
THC 4.6 (2.0–7.1) 2.6 (0.1–5.1) 3.8 (2.0–5.7) 44 ± 44 (8–152)*
Narcotics 2.2 (0.5–4.0) 3.3 (0.5–6.1) 2.6 (1.1–4.1)
Codeine 1.5 (0.0–2.9) 2.6 (0.1–5.1) 1.9 (0.6–3.2) 379 ± 490 (11–1,297)
Morphine§ 1.5 (0.0–2.9) 2.6 (0.1–5.2) 1.9 (0.6–3.2) 70 ± 91 (6–274)
Methadone 0.4 0.0 0.2 5* (n = 1)
Hydrocodone 0.4 0.0 0.2 480 (n = 1)
Tramadol 0.0 0.6 0.2 358 (n = 1)
Beta-blockers 1.5 (0.0–2.9) 0.6 (0.0–1.9) 1.2 (0.1–2.2)
Betaxolol 0.7 (0.0–1.7) 0.0 0.5 (0.0–1.1) 201 ± 16 (190–212)*
Metoprolol 0.7 (0.0–1.7) 0.0 0.5 (0.0–1.1) 44 ± 14 (34–54)*
Metoprolol acid§ 0.7 (0.0–1.7) 0.0 0.5 (0.0–1.1) 109 ± 129 (17–200)
Bisoprolol 0.0 0.6 0.2 64* (n = 1)
Metabolic modulators 0.7 (0.0–1.7) 0.0 0.5 (0.0–1.1)
Methoxytamoxifen 0.4 0.0 0.2 25 (n = 1)
Anastrozole 0.4 0.0 0.2 250 (n = 1)
Data are derived from samples collected in the Goûter (n = 274) and the Cosmiques huts (n = 156). CI, confidence interval; THC, tetrahydrocannabinol
§indicates that this substance was always detected concomitantly with the previous one, within the same urine sample. Only the first substance (i.e.
prednisone, codeine or metoprolol) was recorded for positive cases.
‡benzoylecgonine is the main cocaine metabolite.
*values are derived from confirmatory analyses. Individual data of drug concentrations in positive urine samples are available in S1 Table.
doi:10.1371/journal.pone.0156786.t001
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results indicate that thirty-three urine samples contained more than one drug, suggesting that
some people took multiple medications for the ascent of Mont Blanc.
With regard to pharmacological treatment of acute mountain sickness, the percentage of
urine samples containing acetazolamide appears to be high: our data on Mont Blanc confirms
those reported in a previous survey on Mount Kilimanjaro, showing that 33% of the climbers
were taking acetazolamide [16]. Indeed, history of acute mountain sickness, insufficient accli-
matization and/or lack of previous high-altitude experience (and therefore the fear of being
susceptible to altitude sickness) are likely reasons for frequent acetazolamide use also on Mont
Blanc. Medical guidelines [4] and review articles [12, 21, 22] recommending acetazolamide when
a rapid ascent to high altitude cannot be avoided may also encourage people to use this drug on
Mont Blanc. Such practice is however questionable since the efficacy of acetazolamide for partic-
ularly high and fast climbs such as Mont Blanc (altitude gain of almost 4,000 m within 24-48h)
remains uncertain [12]. Although any pharmacokinetic interpretation must be made with great
caution in the absence of any information regarding drug intake characteristics, our data suggest
“moderate-dose” treatment among Mont Blanc climbers, since the mean urine concentration of
acetazolamide was similar to levels measured 8–24 hours after a single oral dose of 250 mg [23,
24] and 125 mg orally is generally considered “low-dose” treatment. Finally, we cannot exclude
that the use of acetazolamide could be over-detected, since climbers using this drug may urinate
more frequently and thus be slightly oversampled in the population.
Although difficulty in sleeping is a common problem at high altitude, treatment of altitude
sleep disorder with hypnotics is only partially documented and therefore not always advisable,
Table 2. Combinations of drugs found in urine fromMont Blanc climbers.
Substance 1 Substance 2 Substance 3 Goûter hut Cosmiques hut Bothhuts
Number of cases
Acetazolamide Zolpidem 5 2 7
Acetazolamide Hydrochlorothiazide 2 2 4
Acetazolamide Prednisone 3 1 4
Acetazolamide Betamethasone 3 0 3
Acetazolamide Methylprednisone 0 1 1
Acetazolamide Metoprolol 1 0 1
Acetazolamide Zopiclone 0 1 1
Acetazolamide Zolpidem Bisoprolol 0 1 1
Acetazolamide Benzoylecgonine‡ Pseudoephedrine 1 0 1
Acetazolamide Codeine Hydrocodone 1 0 1
Zolpidem Caffeine 1 0 1
Zolpidem Prednisone 1 0 1
Zolpidem THC 0 1 1
Zolpidem Zaleplon 0 1 1
Zolpidem Codeine 0 1 1
Zolpidem Dihydrobupropion 1 0 1
Prednisone THC 0 1 1
Hydrochlorothiazide Prednisone Benzoylecgonine 1 0 1
Total 20 12 32
THC, tetrahydrocannabinol. In addition to the thirty-two cases of drug combinations with two or three substances, one urine sample collected at the Goûter
hut contained five substances: methoxytamoxifen, anastrozole, caffeine, lorazepam and methadone (not shown in the table).
‡benzoylecgonine is the main cocaine metabolite.
doi:10.1371/journal.pone.0156786.t002
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as it should be reserved for those whose sleep problems are very severe [25]. In our study, more
than 10% of the urine samples randomly collected from male climbers contained hypnotics,
which is approximately twice the proportion observed in a large French epidemiological study
[26]. Hypnotic drugs could be harmful to climbers when wake-up occurs shortly after medica-
tion intake (typically 4–5 hours, as climbers usually leave the huts 3 to 4 hours before sunrise),
suggesting possible residual negative effects on vigilance [15], at a time when a high level of
alertness is required. It cannot be excluded that, in this particular setting, even short half-life
benzodiazepine-like agents such as zolpidem may diminish cognitive performance.
Contrary to our hypothesis, performance enhancers were not frequently detected: few urine
samples were found positive for glucocorticoids (despite prospective trials have established a
benefit for the glucocorticoid dexamethasone in the prevention of acute mountain sickness)
[4], and PDE-5 inhibitors were totally absent. The presence of stimulants among urine samples
of Mont Blanc climbers was also marginal (with the notable exception of three samples con-
taining cocaine, the highest concentration suggesting recent use 24h) [27], in contrast to pre-
vious data indicating amphetamine use among climbers in the Swiss Alps [5]. The presence of
tetrahydrocannabinol (THC) in some samples (3.8%) raises concerns about possible impair-
ments of cognitive and psychomotor performance [28], however the long half-life of THC did
not specifically indicate current use.
Finally, the detection of combinations of drugs in our set of urine samples raises questions
about potential adverse effects related to drug interactions among climbers. In particular, it
would be prudent to avoid recommending co-medication with acetazolamide and zolpidem in
the absence of sufficient data [25], and the combination of diuretics (acetazolamide and hydro-
chlorothiazide) may exacerbate dehydration and/or hypokalemia during prolonged strenuous
exercise at high altitude. The issue of dangerous effects of drug-drug interactions in this
extreme environment becomes more worrying considering that climbers may concomitantly
use other classes of drugs not studied here (such as nonsteroidal anti-inflammatory drugs).
We acknowledge several limitations to our blinded urine collection method. First, sampling
was limited to male individuals. Although data are not known precisely, the proportion of
women climbing Mont Blanc was estimated to be between 10 and 20%. In our male population,
the absence of information on subjects (such as demography, mountaineering experience, per-
formance, or medical conditions) prevented us to know why drugs were used, and in particular
if the use of prevalent drugs such as acetazolamide or zolpidem could be problematic or on the
contrary beneficial. Second, we probably underestimate the prevalence of drug use because of
the withdrawal of all possibly contaminated samples from analysis (see Methods). Our
approach may appear too conservative considering the relatively low cross-contamination rate
(<13%). However, we did not use a cut-off value (e.g. of 15%) to confirm whether a sample
was contaminated or not, since the titration experiment was limited to only a small selection of
drugs, with fixed concentrations. We propose a possible improvement of the sampling system
to minimize potential cross-contamination and therefore missing values (see legend to Fig 1).
Third, because strict anonymity was ethically obligatory, we did not monitor the rate of redun-
dant samples (i.e. coming from the same individual). At the Cosmiques hut, where the sampler
operated only at night, we speculate that redundancy was low since 1) mountaineers are usually
in a hurry to leave the hut (<1 hour between awakening and departure) leading them to uri-
nate only once; and 2) six toilets/urinals were simultaneously accessible. At the Goûter hut
(where the sampler operated from 01:30 a.m. to 09:00 p.m.), the fact that people did not use the
experimental urinal during sleeping time, and furthermore could always choose between 11
toilets/urinals during the sampling period leads us to speculate that redundancy was also lim-
ited. However, some people being creatures of habit, they might use the same urinal each time,
thus it is not excluded that our results may have overestimated drug use. Alternatively,
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assuming that redundancy rate was comparable between people using drugs and those who did
not suggests that the overall impact of redundancy on our prevalence data remained low.
Fourth, since one urinal was fitted with the sampling system in each hut, climbers who never
used this urinal were not included in the study population. Our sample would have been more
representative of the climbers’ population if all urinals had been equipped, however such a
design would have probably increased the rate of redundant samples. Fifth, as the automated
sampling procedure could not distinguish a single dose from regular long-term use, data inter-
pretation must be cautious, especially for prevalent drugs such as hypnotics [29]. However,
whatever the therapeutic class, it seems difficult to compare our international climbers with
population-based cohorts. Indeed, there is a lack of self-reported prevalence data on drug use
in the general population and little data from international studies are readily available. Finally,
it would have been interesting to investigate nonsteroidal anti-inflammatory drugs in the pres-
ent study, as these compounds are commonly used by mountaineers for preventive/prophylac-
tic treatment or acute mountain sickness, and may furthermore enhance performance by
reducing the chance of getting sick. However, such analyses were not conducted since these
molecules are not on the WADA list of prohibited substances and therefore WADA-accredited
laboratories do no implement assays for these drugs.
Conclusions
We show that about one third of the urine samples collected from a random sample of male
climbers contained one or several drugs. This suggests that drug use is frequent among climb-
ers on Mont Blanc. The drugs used seem primarily intended to alleviate symptoms related to
altitude sickness, but would not represent a doping behavior. Alternatively, the use of acetazol-
amide, particularly as a preventive medication, can be viewed as “doping” since it may improve
performance at high altitude by decreasing the chance of getting sick. The relatively high preva-
lence of hypnotics, as well as the use of combined medication (presumably with limited knowl-
edge of potential drug-drug interactions and adverse effects) in this hazardous environment
could affect climbers’ safety.
A future perspective is to extend this novel sampling method to other contexts, where infor-
mation is needed on the prevalence of the use of drugs while limiting selection bias. Examples
might include research on the prevalence on doping among athletes participating in popular
sporting events (such as endurance competitions, where urinals are generally available on site)
which may be relevant for anti-doping policies; studies on psychotropic substance use among
drivers (by using gas station bathrooms) for the purposes of road safety; and prevalence of
drug abuse among participants to social mass meetings, e.g. popular music festivals. It may be
worth asking why similar studies have not been previously implemented during popular sport-
ing events. Ethical aspects might be one reason. Even in our study, which involved a sport not
subject to anti-doping rules, respecting strict anonymity was a key point requested by the ethics
committee. It can be therefore speculated that if such a program should be implemented in a
competitive sport, investigators should take all necessary measures to ensure that their data
cannot be used for other purposes than science (e.g. doping control).
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